Drug Profile
MSI 136
Latest Information Update: 04 Dec 1995
Price :
$50
*
At a glance
- Originator Genaera Corporation
- Class Amino acids; Antibacterials; Antineoplastics; Peptide antibiotics
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Periodontal disorders
Most Recent Events
- 04 Dec 1995 Discontinued-Preclinical for Cancer in USA (Unknown route)
- 21 Nov 1995 New profile
- 21 Nov 1995 Discontinued-Preclinical for Periodontal disorders in USA (Unknown route)